CytoSorbents Corporation (CTSO)

[techxen]

"CTSO is in the early innings of a palatable growth story"

Andrew D’silva must have liked what he heard on the Q3 call in November and the follow-up Q4 pre-announcement.

"We feel comfortable with our estimates at this time, as the sequential top line increase we are modeling is relatively modest and is below historical growth trends, despite the fact CTSO recently obtained a dedicated reimbursement code in its largest market of Germany. As such, we believe the Street’s estimates, which are mixed but relatively close to ours, are reasonable as well. We continue to believe CTSO is in the early innings of a palatable growth story and will continue to benefit from: its 15 at the start of ’16); notable strategic partnerships; a dedicated reimbursement procedure code established in Germany; increased interest in new indications such as CAR-T therapy; expanding CytoSorb (CS) distribution footprint." Their last price target I saw was a conservative $11.25.